Category - Developments

Developments

Altamira Therapeutics establishes OTC Consumer Health business unit

Altamira Therapeutics (NASDAQ:CYTO) established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio, its nasal spray for the protection against airborne viruses and allergens. OTC...

February 4, 2022

Developments

Aravive doses first patient in Phase 2 clear cell renal cell carcinoma trial

Aravive (NASDAQ:ARAV) dosed the first patient in the Phase 2 portion of a Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). “Safety and preliminary activity data...

January 31, 2022

Developments

Talkiatry completes $37-million Series A financing

Closely-held Talkiatry, a provider of in-network psychiatric care, completed its $37-million Series A financing with an additional $17-million from Left Lane Capital. The latest round of funding comes just five months...

January 27, 2022

Developments

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Results of a non-clinical research study demonstrated that Hepion Pharmaceuticals’ (NASDAQ:HEPA) clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse...

January 26, 2022

Developments

ENDRA partnering study of TAEUS with Shanghai General Hospital

ENDRA Life Sciences (NASDAQ:NDRA) received Institutional Review Board approval from China’s Shanghai General Hospital for the first clinical study, expected to begin in 2022, of ENDRA’s Thermo Acoustic Enhanced...

January 24, 2022

Developments

Altamira’s Bentrio nasal spray approved in Malaysia

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio nasal spray has been approved by the Medical Device Authority of Malaysia for the protection against airborne allergens and viruses and is cleared for commercialization in...

January 21, 2022

Developments

Dyadic introduces novel method to produce synthetic cannabinoids

Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...

January 21, 2022

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Developments

Sigyn Therapeutics featured in BioSpace, twice

BioSpace, a leading life sciences publication, featured Sigyn Therapeutics (OTC:SIGY) and its novel extracorporeal blood purification technology twice in January. One article profiled the company and its Sigyn...

January 19, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Category - Developments

Subscribe